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We provide more evidence on the functional relationship between willingness to pay for 
risk reductions and age (the senior discount). We overcome many of the limitations of 
previous literature that has dealt with this issue, namely, the influence of the 
assumptions used in statistical models on the final results. Given our large sample size 
(n=6024) we can use models that are very demanding on data. We use parametric 
(linear, quadratic, dummies), semi-nonparametric and non-parametric models. We also 
compare the marginal and the total approach and we show that they provide similar 
results. We also overcome one of the limitations of the total approach, that is, we 
include the effects of socioeconomic characteristics that are correlated with age 
(education and income). Our main result is that all these different approaches produce 
very similar results, namely, they show an inverted-U relation between the Value of a 
Statistical Life and age. Those results can hardly be attributed to problems of 
collinearity, omitted variables or statistical assumptions. We find a clear senior discount 
effect. This effect seems concentrated on those who have lower education and income 
levels. We also find that the Value of a Statistical Life Year increases with age.  
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One of the most relevant concepts in Cost-Benefit Analysis is the Value of a Statistical 
Life (VSL). The VSL is defined as the marginal relation of substitution between wealth 
and the risk of death. In practice, it is usually estimated from the amount that a subject 
is willing to pay (WTP) for a small mortality risk reduction (Dp) as WTP/Dp. For 
example, if a subject is WTP €30 for a 2 in 100,000 mortality risk reduction, the VSL 
would be 1.5 million euro (€30x100,000/2). One issue that has received considerable 
debate in the literature on VSL is the so-called “senior discount”, that is, whether VSL 
should be age-related, more specifically, would different (lower) VSL be applied to 
older people? This also has very important consequences over another key concept, 
namely, the Value of a Statistical Life Year (VSLY).  
 
The value per statistical life year (VSLY) is an approach for adjusting VSL estimates to 
reflect differences in remaining life expectancy. In some cases, researchers simply 
estimate the VSLY dividing the VSL by the discounted expected number of life-years 
remaining for the average individual studied. That is, they assume that the VSLY is 
constant. In this paper, given our large database, we do not use such restrictive 
assumption since we estimate age-specific values of VSL. To estimate VSLY, we have 
annuitized age-specific VSLs based on age-specific years of life expectancy and we 
obtain age-specific VSLY values.  
 
In many areas, like air pollution or health care, where most of the benefits fall on old 
people, the VSLY could be even a more relevant concept than the VSL. In fact, in the 
economic evaluation of medical technologies life years (or Quality-adjusted life years –
QALYs-) are more often used as a measure of benefit than lives. Traditionally, many 
regulations have used the same VSL regardless of age and a constant VSLY. However, 
if VSL does not depend on age, life years of those with lower life expectancy (usually 
old people) receive higher values than those with higher life expectancy (usually young 
people). It is then quite relevant to have clear evidence of the existence or not of the 
“senior discount” and its implications for policy. This paper aims at shedding more light 




Viscusi [25] suggests that the existence or not of a senior discount should be based on 
individual’s willingness to pay for risk reduction. However, Crooper, Hammit and 
Robinson [8] indicate that “few studies provide a clear test of the effect of age on VSL”. 
They point out to statistical problems encountered in many studies, like imposing a 
certain functional form (linear or quadratic) and they suggest that more flexible 
functional forms are needed. Kriström [13] and McFadden [16, 17], among others, 
emphasize the limitations of the parametric approach since the statistical assumptions 
on the response probability function are quite demanding and erroneous assumptions 
may lead to a remarkable bias in the estimation of the welfare measure. In the context of 
mortality risk valuation, Alberini [1] finds that the age effects in mortality risk valuation 
are not robust to researchers’ choices about these assumptions.  Krupnick [14] 
emphazises that most studies focus on the marginal effect of age but not on the total 
effect. The marginal effect approach tries to estimate the relationship between age and 
WTP, holding (theoretically) other variables constant. However, there are important 
issues of collinearity (age is a proxy for other variables) and omitted variables, within 
this approach. Krupnick [14] suggests that some of these issues can be handled under 
the total effect approach. Here, age is treated as a proxy for variables that change with 
age. We estimate total effect dividing the sample into different age groups and 
comparing WTP between those groups. Very few papers supplement the marginal 
analysis with total effect analysis probably because it is necessary to have a large 
sample size with enough seniors in order to implement this approach. The problem of 
the total approach is that we do not know if any senior effect is related to age per se or 
to some characteristics that are age-related unless the analysis is conducted in subgroups 
of similar characteristics. However, this requires a very large sample size since some 
groups (e.g. old people with high education and high income) quickly become too 
small. 
 
Our study overcomes most of these problems given the large sample size (n=6024) we 
have. First, we estimate both marginal and total effects. We are not aware of any other 
paper that has combined the two approaches. Second, within marginal effect we use 
several specifications of the age variable, namely, we use linear, quadratic, dummies 
and semi-nonparametric. We use the semi-nonparametric specifications proposed by 
Alberini [1] since she showed that they may generate very different (and opposite) 
results to those obtained from parametric techniques. Our results are robust to those 
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different specifications. Third, we used non-parametric methods in order to apply total 
effect analysis. In this way, we can overcome the problems of collinearity and omitted 
variables that can influence the results of the marginal approach (Krupnick [14]) and 
results are not influenced by the assumptions used in the statistical models. We estimate 
WTP within groups that are homogeneous not only in terms of age but also in income 
and education. In this way, the total effect analysis conducted in this paper overcomes 
one of the problems of this approach, namely, that it does not disentangle the effect of 
different variables that are correlated with age.  We can also make a distinction between 
age groups that they all fall within the concept of “senior”, that is, those who are 
“younger” seniors (say 60-75 years old) and older seniors (more than 75). There is very 
little evidence in the literature between WTP within senior age groups. Finally, 
following Viscusi and Hersch [26] we also estimate the relationship between the value 
of a statistical life year (VSLY) and age. In summary, the main contribution of this 
paper is to calculate age-specific values for VSL using techniques that avoid the main 
biases that, according to the literature, could affect previous calculations.  
 
The main result that we obtain is that all these different approaches (parametric, 
semiparametric, non-parametric, marginal and total effects) produce very similar results 
and it confirms previous evidence, namely, the relationship between VSL and age is  
inverse U-shaped. Those results can hardly be attributed to problems of collinearity, 
omitted variables or statistical assumptions. We find a clear senior discount effect. This 
effect seems concentrated on seniors who have lower education and income levels and 
on older seniors. We also find that VSLY increases with age specially above 65. 
 
Our paper proceeds as follows. First we describe the structure of the survey. Second, we 
justify the quality of our data, applying some validity tests. Krupnick mentions as 
validity tests “that variables expected to affect WTP do in fact have such an effect” (p. 
268). However, Loomes [15] also mentions a different kind of validity tests that are the 
mirror image of those mentioned by Krupnick, namely, that variables that are not 
expected to affect WTP do not in fact have an effect. One paradigmatic case that 
variables that are not expected to affect WTP end up influencing WTP is framing 
effects. We study to what extent framing effects influence our data. We show that our 
data pass these validity tests. The paper then proceeds to present the main econometric 
models we use. This is followed by the presentation of the main results, that is, the 
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relationship between WTP and Age. We present first the results of the marginal 
approach, using parametric and semiparametric techniques. We then present the results 
of the total effect approach using non-parametric techniques. Finally, discussion and 
conclusions close the paper. 
 
2. Survey design 
To study the relationship between WTP and Age we estimated individual willingness to 
pay for reductions in the risk of mortality due to acute myocardial infarction (AMI). We 
used this case for two reasons. One is that we already had experience with this good 
since it was used in previous work ([19]). We used the same framing and visual aids 
that were developed for the former study. The second reason is that, in the former study, 
we observed that subjects did not need very long explanations of the nature of an AMI 
and its consequences. Most people are familiar enough with the concept of AMI so a 
short explanation is enough for them to understand the health problem we are dealing 
with. We thought that we could use a simpler questionnaire in this case than in [19]. 
The questionnaire we used for the present survey was included in a general survey that 
was conducted by ASEP (http://www.jdsurvey.net), a private consulting firm that 
carried out every month from 1986 to 2011 a survey on “Spaniards’ Public Opinion”. It 
was a Personal Face to Face survey, representative of the Spanish population 18 years 
and over. Sample size was 1200 subjects each month. It is a stratified random sample. 
The strata are 1) the Autonomous Regions and 2) Municipalities grouped by population 
size. There is a random selection of municipalities and electoral districts within each 
municipal stratum and Autonomous Community. Household selection is conducted 
through random route procedures within each electoral district. Final selection of 
respondent in each household is based on gender and age quotas or on Kish's Tables. 
We inserted our survey in five of their waves (December 2005, February, March, April 
and May 2006) for a total sample size of 6024 subjects.  
 
The first part of the text was aimed at explaining what an AMI is and the concept of risk 
of mortality linked to it. It was explained that after an AMI some people die 
immediately and some other people survive. However, in the most acute cases, the heart 
of those people who survive is damaged and they need to take medicines. In spite of 
taking these medicines (medicine X in the survey), 17% of these people die the first 
year after the heart attack. After this first year, only a very few people die from the 
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damage caused by an AMI. The data were obtained from Randomized Controlled Trials 
[20]. The status quo was then to take medicine X, pay nothing and accept a 17% risk of 
death the first year after the AMI. 
 
The second part was devoted to the preference elicitation questions. Subjects were 
asked to assume that a new medicine (medicine A) was introduced providing a lower 
mortality risk. A visual aid was included to help respondents to understand better the 
risk reduction provided by the medicine. The treatment had to be followed for one year 
after the AMI. 
 
We used three different elicitation procedures in order to test for the influence of 
framing effects. Each survey was divided in 6 groups of about 200 subjects each. We 
then have a total of 30 different subgroups (5 waves x 6 subsamples in each wave) 
divided as follows:  
A. Elicitation Procedure 1 (EP1): Double-bound Contingent Valuation. Groups 1 to 
12 (December and February surveys). Each subject was asked if s/he would be 
willing to pay or not a certain amount of money (initial bid) monthly, for one 
year, in order to take medicine A, which would reduce the risk of death by 3% 
(from 170 in 1000 to 140 in 1000) the first year after the AMI. If s/he accepted 
this amount next bid was higher, otherwise lower. An “I do not know” answer 
was also allowed. The distribution of bids by group can be seen in Table I. 
B. Elicitation Procedure 2 (EP2): Groups 13 to 20 (the six Groups of March and 
two Groups of April) were allocated to this procedure. In this case, subjects were 
told that the effect of medicine A could be high (final risk Q) or low (final risk 
R, Q<R) depending on patient’s characteristics and that there was a medical test 
that could tell them if they were in one group or another. They were also told 
that the cost of the medicine was not certain and it could also be high (Y€) or 
low (Z€). They were asked four questions depending of the different 
combinations of effectiveness (high-low) and cost (high-low). For example, they 
were told “the medical test tells you that you are in group 1. Medicine A will 
reduce your risk from 170 in 1000 to Q. The cost for you is Z€”. This represents 
the high(effectiveness)-low(price) combination. Then, three more questions 
were asked using combinations high-low, low-high and low-low. In summary, 
the subject had to make four binary choices. An “I do not know” answer was 
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also allowed. The options that the subjects had to compare to the status quo 
(17% of risk, no cost) can be seen in Table I.  
C. Elicitation procedure 3 (EP3): This group was very similar to EP2 since subjects 
always had to do four binary choices. However, in this case, all options had the 
same price and they were different in term of the risk reduction. That is, they 
were told that the effect of the medicine was not certain and that it worked 
differently in four groups of patients. While initial risk was always 170 out of 
1000 final risk could take four different values. Again, the question was “the 
medical test tells you that you are in group 1. Medicine A will reduce your risk 
from 170 in 1000 to Q. The cost for you is Z€”. The cost (Z€) was always 
constant. In practice, they had to say in which cases they would pay Z€ and in 
which cases they would not. An “I do not know” answer was also allowed. The 
options that the subjects had to compare to the status quo can be seen in Table I. 
 
This design makes possible to conduct several tests about the quality of the data in line 
with the suggestions of Krupnick [14] and Loomes [15], that is, responses should be 
sensitive to theoretically relevant factors and insensitive to theoretically irrelevant 
factors. One different between our setting and other settings used in the literature on the 
value of a statistical life, is that the risk reduction we use is significantly larger than 
other studies that have used very small risk reductions (e.g. 1 in 100.000 or in 10.000). 
One problem of this is that our estimations of VSL cannot be directly compared to the 
value of VSL estimated in those settings. However, the main objective of this paper is 
not to estimate VSL but the relationship between VSL and age and this can be done 
using a 3% risk reduction, as it is our case. Apart from that, the use of larger risk 
reductions may have some advantages, since there is evidence that subjects have 
problems in working with very low probabilities. In any case, we believe it is important 
to use risk reductions that correspond to the health setting in order to obtain conclusions 
that are relevant in the allocation of health care resources. 
 
2.1. Sensitivity to theoretically irrelevant factors 
Three kinds of effects are analysed here: 
1. Framing effects: we test if WTP depends on the elicitation procedure used in our 
experiment. In order to do this, we compare the probability of accepting a bid 
for a 3% risk reduction in EP1 with the probability of accepting the same bid for 
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the same risk reduction in EP2 and EP3. Since the first response to the DBDC is, 
theoretically, the most unbiased one we compare the probability of accepting the 
first bid in EP1 with the probability of accepting the same bid in EP2 and EP3. 
2. Ranking effects: we test if WTP depends on the position (best, intermediate, 
worst) of the alternative within the choice set. According to Parducci’s Range-
Frequence model [18] the perceived utility of an object depends on its ranking 
within a context. For example, in subgroup 13 the alternative (3% risk reduction, 
240€) was the worse deal in the choice set (it provided the smallest risk 
reduction at the highest price) while in subgroup 16 it was the best alternative in 
the choice set (highest risk reduction at the lowest price). According to 
Parducci’s model the probability of choosing this alternative against the status 
quo should have been higher in 16 than in group 13. That is, the higher the 
position in the rank of the choice set the higher the probability of choosing this 
alternative against the status quo. 
3. Probability framing: Within EP1 we tested if the numerical way of presenting 
the data had some influence. While in most of the cases risks were presented as 
X out of 1000, in some groups (6 and 12) we used percentages (X out of 100). 
This is the difference between groups 3 and 6 and between 9 and 12. 
4. Order effects: within EP3 we tested the existence of order effects. This was done 
comparing groups 21 vs 22 and 23 vs 24. The questions were the same in groups 
21-22 and in groups 23-24. In groups 21 and 23 subjects started with the 
smallest risk reduction and were progressively shown higher risk reductions. In 
groups 22 and 24 the order was reversed. 
 
2.2. Sensitivity to theoretically relevant factors 
Two kinds of effects are analysed here: 
1. We analyse the sensitivity of responses to the size of the good, in our case, risk 
reduction. The existence of scope effects is tested comparing the results of 
elicitation procedures 1 and 3 (EP1 and EP3). We do not use EP2 since we do 
not have enough variability in the levels of risk reduction analysed and we 
cannot estimate survival curve reliably. The response probability function was 
estimated using the bids that are common to EP1 and EP3, that is, 30€, 90€, 
240€, 720€ and 1500€. Scope effects will be estimated comparing the mean 
WTP for a 3% risk reduction in EP1 with the corresponding mean WTP for 
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smaller risk reductions in EP3. We can also conduct a further consistency test, 
that is, we can test if WTP for the same risk reduction (3%) is similar in both 
groups. 
2. We analyse if WTP changes in the predicted direction with personal 
characteristics such as income. 
 
It can be seen that the design is very demanding in relation to the consistency checks 
we can conduct. We thought that it was very important that we could show that our 
data were consistent. One reason is that since our survey was a shorter version of the 
more in depth survey we conducted previously, we had to be sure that the quality of 
the data was good. It would have been simpler to use the common Double (or 
Single) Bound Dichotomous Choice format to all cases but we thought we needed 
more checks on the validity of our data. However, one drawback of using this 
design is that the number and type of questions asked to subjects was different in 
each framing. For this reason, in order to study the relationship between WTP and 
Age we used only one response from each individual, that is, the one corresponding 
to the 3% risk reduction from 17% to 14%. The reason is that this risk reduction was 
asked to all subjects. For EP1 we use only the response to the first bid. For EP3 we 
only have one observation for the 3% risk reduction so this is the response we use. 
Finally, in EP2 we have two responses for the 3% risk reduction. In this case, we 
only use the response to the first question about a 3% risk reduction1. 
 
3. Econometric models 
We assume that the subject has to choose between two different scenarios with different 
levels of risk of death ( , ) and income (Y,Y-Ak). We consider the amount A* that 
would make the individual indifferent between both options: 
 
    
    
                                                
1 In order to test how sensitive are our results to this way of analyzing the data we replicate our analysis 
using only the response to the first bid in the traditional DBDC approach. That is, only the data of two 









where  is a vector of respondent’s characteristics (including age), and  is an 
stochastic component representing the other components that are unobservable to the 
researcher . 
 
The probability of a “yes” answer we may be expressed as:  
 
.        (3) 
 
This response probability model may be estimated using parametric, semi-
nonparametric and non-parametric methods. In the next sections, we explain the 
different approaches and how the effect of the age has been included. In this way we 
will test to what extent our results are influenced by the statistical assumptions of the 
models.  
 
3.1. Parametric approach 
Parametric methods introduce different distributional and functional assumptions upon 
the WTP function. We use a log-logistic model [4] because it fits the data better than 
other models. This model assumes that WTP is an exponential function of a linear 
combination of individual characteristics  and additive error term that follows a 
logistic distribution [10]. Therefore, individual willingness to pay for the improvement 
in the level of mortality risk will be non-negative, which is a desired feature for this 
study since the respondent should have non-negative preferences about reductions in 
risk mortality. The response probability function is specified as: 
 
        (4) 
 
Within this framework, the effect of age on individual’s responses can be included in  
using different specifications. Following to Krupnick [14], we use several specifications 
for the age variable, namely, linear, quadratic and two specifications for dummies.   
 
 
3.2. Semi-nonparametric approach 
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An alternative procedure consists in semi-nonparametric methods [7]. They reduce the 
sensitivity of results to specific parametric assumptions about the form of the WTP 
distribution.  This is achieved replacing the linear combination in the WTP function 
with a Fourier flexible form [9].  As a result, the models follow more closely the data 
and are less influenced by statistical assumptions. The probability is expressed as: 
 
  (5) 
 
where , ,  and denote the coefficients to be estimated, M and J are positive 
integers,  is a vector of positive and negative integers that form indices in the 
conditioning variables and specify which variables in  are combined to obtain the 
transformed variables, and the function  is a scaling function. This scaling function 
subtracts of each variable in  its minimum value and then divide by its maximum and, 
finally, multiply by . As a result, each scaled variable lies in the interval 
. This scaling process is needed to avoid periodicity in the model [9]. 
Following Creel and Loomis [7] and Cooper [6] quadratic terms are not included in the 
Fourier expression.  
 
In this paper, the cos and sin transformations will be applied over the age variable, with 
the purpose of capturing non-linearities associated to this variable.  
 
3.3. Non-parametric approach 
Non-parametric methods have the advantage of avoiding statistical assumptions on the 
response probability function, as well as the simplicity of estimation. Consider K 
different bids,  where A1< A2 < ... < AK. Bids are assigned to people 
from K subsamples of size n1, n2,, ..., nK, with  being the sample size. Let dk 
denote the number of people from subsample Ak who accept the bid offer (or number of 








































proportion of yes answers to bid Ak from subsample nk would then be , and the 
sequence of affirmative answer proportions would be . 
 
A common assumption used in non-parametric estimation is that this sequence of 
proportions has to be monotonically non-increasing, and when the assumption is 
violated (  for any k), the sequence is forced to be monotonic. In this sense, 
Ayer et al. [3] propose to replace the proportions  and that violate monotonicity 
by . If after that the sequence still violates monotonicity for other 
pairs of bids, the same procedure is repeated until the series becomes monotonic, i.e. 
until 1 ³ 2  ³ ... ³ K. 
 
There are three basic ways to estimate non-parametrically the response probability 
function out of the monotonic sequence (see, for instance, [5]): the Paasche procedure, 
the Laspeyres procedure; and the intermedium one. The estimated value of the 
probability of acceptance of the offered bid, , will be equal to: 
 in the  Paasche procedure,  
 in the  Laspeyres procedure, 
 in the intermedium procedure, being this expression 
the line connecting the points  y .  
 
From these procedures, Laspeyres is the most conservative and it is the method we will 
use. Moreover, this procedure does not require any assumption upon the upper 
distribution endpoint, that is, the value of that verifies K+1=0.  
 
Non-parametric methods have some disadvantages as their relative inefficiency 
compared to a correctly specified parametric model, or the difficulty to include 
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3.4. Mean WTP estimate: marginal and total effects 
In parametric and semi-nonparametric methods, mean WTP is estimated integrating the 
response probability function over the interval [0, AK]. This maximum bid truncation is 
recommended by some authors because no information is available beyond that point 
[4, 10, 23]. In the case of non-parametric methods, mean WTP is estimated in a similar 
way, that is, calculating the area under the probability of acceptance curve in the 
interval [0, AK] (Kaplan-Meier-Turnbull estimator, [24]). 
 
Given these models we can estimate the senior discount using the marginal effect of age 
on WTP or using the total effect approach. Marginal effect will be estimated using 
parametric and semi-nonparametric models. In parametric models the way of testing for 
the existence of the senior discount will depend on the functional form used. If age is 
entered linearly, there will be a senior discount if age coefficient is negative; if we add a 
quadratic term the function will be inversely U-shaped having the maximum before old 
age; if age is entered as a dummy variable the coefficient for seniors is negative 
(assuming young people is the base category). In semi-nonparametric models it is not so 
simple to observe the existence for the senior discount. First, it is important to check 
that the coefficients of the cos and sin transformations are significant. If they are, it 
implies that the model is capturing non-linearities that are neglected by our parametric 
models. If they are, we need to estimate WTP conditional on age to test if the senior 
discount is observed. 
 
Total effect implies estimating different WTP for each age group. We could also use 
parametric and semi-nonparametric models in this case. However, since total effect can 
be estimated without any parameterization we think it makes more sense to use non-
parametric methods to apply this approach. In this way we avoid the problems observed 
by Alberini [1] and Robinson and Hammit [22] that were explained in the Introduction 
of this paper. 
 
3.5. Value of statistical life year (VSLY) 
The value of a statistical life year conditioned on age (VSLYA) will be computed as in 




𝑉𝑆𝐿𝑌% = 𝑟(𝑉𝑆𝐿%)1 − 1 + 𝑟 -. 																																																																																																					(6) 
 
where VSLA stands for the Value of Statistical Life at age A, r is the discount rate and L 
is the remaining life expectancy at age A. If VSL declines in the same proportion as life 
expectancy with people grew older, VSLY will be constant or independent of age. This 
is the usual assumption used in the literature. However, if VSL declines less than 
proportionally with life expectancy, VSLY will increase with age. We believe it is 
important to use our data to compute VSLY given the large amount of subjects older 
than 65 that we have in our sample (18.97%). Estimations of VSLY based of revealed 
preferences often rely on data from the labour market and there are hardly observations 
of subjects older than 65. Also, databases that use stated preferences do not have usually 
enough observations of subjects older than 65 in order to make a distinction within this 
group. This is important since some policies specially benefit older seniors (75 and 
above). Some examples of those policies are, clean air policies (in the environmental 
area) or cancer drugs (in the health policy area). Viscusi and Hersch [26] (p.950) show 
that “the VSLY varies from youngest to oldest by a factor of three for men and a factor 
of two for women”. However, by oldest they refer to those in the 55-64 range. It is 
important to know if the pattern follows for older cohorts. 
 
4. Results2 
The number of subjects we finally used was 5566 and not 6024 as 458 chose the option 
“I don`t know” in the WTP question. These 458 individuals were distributed between 
surveys and frames as follows: December (n=61), February (n=64), March (n=98), 
April (n=127), May (n=108), EP1 (n=125), EP2 (n=139), EP3 (n=194). The distribution 
of the remaining 5566 individuals was: December (n=1146), February (n=1145), March 
(n=1103), April (n=1079), May (n=1093), EP1 (n=2291), EP2 (n=1458), EP3 (n=1817). 
No statistically significant differences among the samples were found [27].  
 
More than 35% of subjects did not respond to the question of income level. In order not 
to lose those observations we looked for a proxy variable. Social Status performed very 
well since it is closely related to income. This is a Likert type scale of self perceived 
                                                
2 There is supplementary material, with more results, that is available upon request from the authors for 
the reader interested in more detailed information.  
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Social Status. It goes from 0 -Lowest Social Status- to 8 -Highest Social Status-. The 
correlation between these two variables (Income and Social Status) was measured using 
the Gamma statistic, obtaining a value of 0.87, close to 1, the strongest level of 
association. In general, the sample was representative of the Spanish population and 
there were no differences in sociodemographic characteristics between the three 
framings used. 
 
4.1.  Data quality 
4.1.1. Sensitivity to irrelevant factors 
The different tests showed the lack of sensitivity of the responses to theoretically 
irrelevant factors (p>0.1). The proportion of subjects choosing one alternative or the 
status quo was very similar in all contexts. No evidence of statistically significant 
framing effects or order effects was found. We did not observe statistically significant 
effects either when probabilities were presented as number of events in a group of 100 
or 1000 subjects.  
 
4.1.2. Sensitivity to relevant factors 
The main “relevant factor” was the sensitivity of WTP to the size of the risk reduction. 
In order to test for scope effects estimates of mean WTP were obtained using the 
nonparametric Turnbull estimator. Mean WTP for a 3% risk reduction was clearly 
higher in EP1 than the corresponding means for smaller risk reductions in group EP3 
(p<0.01)3. Also, there were not statistical significant differences (p=0.11) between the 
3% risk reduction in groups EP1 and EP3. Finally, the proxy variable for income was 
significant in the direction predicted by theory. 
 
In summary, the data seem to behave quite well in terms of their relationship with 
theory. They are sensitive to things that should matter and not sensitive to things that 
should not matter. Given that the data are internally consistent we proceed to pool the 
responses obtained from the three elicitation procedures considered.  
 
4. 2. Marginal Effect: parametric and semi-nonparametric models 
                                                
3 One-sided approximate significance level obtained following Poe et al. [21] with non-parametric 
bootstrapping and 10,000 replicates. 
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The main results of the parametric and semi-nonparametric models can be seen in 
Figure 1. The dependent variable is a binary choice variable that takes a value of 1 if the 
individual answered yes to the WTP question and 0 if the individual answered no. 
Together with age, we have included in these models several independent variables to 
capture the possible influence of other important factors on WTP, namely gender, level 
of education and income. Definitions of the variables are as follows. Gender is a binary 
variable where the value 1 means male and the value 0 represent the female category. 
Income and Education are two binary variables built from the variables Level of social 
status and Level of education, respectively.  Income takes a value to 1 when the variable 
Level of social status is higher than 3. Education takes a value of 1 when Level of 
education is higher than lower secondary. The cutoff points were chosen to produce two 
different groups of approximately the same size in order to increase the statistical power 
of the tests in the total effect analysis. The coherence of the resulting subgroups was 
checked. Level of social status is assumed to be a proxy for income as explained above. 
The values of some of these covariates was not reported by 30 individuals, resulting a 
final sample size of 5536 individuals (n=2279 in EP1, n=1449 in EP2, and n=1808 in 
EP3). 
 
The coefficient of age for the linear model is negative and statistically significant 
(p<0.05), suggesting lower WTP as age increases. The quadratic term is also 
statistically different from zero and negative so the function is inversely U-Shaped. 
Figure 1 shows that the function peaks at age 39 (Monthly WTP= 942.9€). If we set up 
this value as 1, the relative value for a 65 year old would be 0.87 and 0.70 for an 80 year 
old. The two models with dummies also provide a similar picture. In the case of the 
semi-nonparametric model, we have applied only the cos and sin transformations to the 
age variable, since these transformations were non-significant for the ln(bid) variable. 
The results for the semi-nonparametric model are very similar to the quadratic model 
except for the fact that the quadratic model seems to understate WTP for older seniors 
(over 75). In relation to sociodemographic variables, we obtain that Gender is not 
significant in any model while Education and Income are significant: subjects with 
higher income and higher education have higher WTP. 
 
4.3. Total effect: non-parametric models 
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Results for the total effect non-parametric model can also be seen in Figure 1. These 
results basically confirm what we have observed in parametric and semi-nonparametric, 
namely, WTP has a concave relationship with age, with the maximum located at around 
40 and continuously falling with age from that point. However, the non-parametric total 
effect model increases the senior discount, since WTP for subjects older than 60 is 
lower than what is predicted by any parametric or semi-nonparametric models. Now the 
65 years old would have a WTP that is 67% (instead of 87%) in relation to the subjects 
with highest WTP and 75 years old would have a WTP that is 62% in relation to the 
maximum WTP. However, it falls quite sharply for those who are over 80 that have a 
WTP that is only 36% of the maximum.  
 
One of the limitations of the total effect approach is that it is difficult to disentangle the 
effect of the different variables that are correlated with age. In our case, given the large 
sample size, we can apply the total effect for more uniform groups. In Table II we see 
non-parametric WTP for Age-Education groups and for Age-Income groups. Tests for 
differences in mean WTP are reported in Table III. The senior discount is independent 
of the level of education but is not independent of the level of income, since it 
concentrates only on low-income subjects. Finally, we can even do finer categories 
(although sample size becomes dangerously small for some of them) (see Tables II and 
III). When we do this, we see that the senior discount is related more to the income level 
than to the education level. When income level is high, we do not observe any senior 
discount, independently of the education level. When income level is low, we observe 
the senior discount, independently of the education level. 
 
4.4. Value of Statistical Life Year 
The relationship between Age and VSLY can be seen in Figure 2. We can see that the 
relative values are very similar for men and women. We show the results for the 
semiparametric model but the rest of models provide a similar perspective. Our results 
are a little bit different to those obtained by Viscusi and Hersch [26]. We obtain a very 
similar ratio of the VSLY for men and for women while it is different for them. In their 
case, it was about 3 for men and about 2 for women. In our case, it is about 1.7 for men 
and 1.5 for women (60 years old vs 20 years old). However, we can see that this ratio 
accelerates around 65. This is not surprising given that WTP changes much less with 
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age than life expectancy. The relative value of a life year for an 85 year old is about 3.5 
higher than the corresponding value of a 20 year old.   
 
5. Concluding remarks 
We have presented in this paper what we believe is one of the more solid pieces of 
evidence on the existence of the senior discount. Most of the methodological problems 
that have been shown to affect the calculation of the senior discount do not apply to our 
paper. Of course, it does not mean that the paper is free from limitations. First, we have 
used a case study where risk reduction is much higher than the usual papers that have 
estimated the senior discount. In our case, we have been dealing with a health problem 
that is (more or less) familiar to most subjects and we have been using a 3% risk 
reduction in mortality, far larger than most of the studies on the VSL where risk 
reductions are usually presented as X in 100,000 or in 10,000. The study of Alberini et 
al. [2] presented risk reductions of 1 and 5 in 1000 and they are amongst the largest risk 
reductions we have seen in order to estimate VSL. For this reason, we think that the 
implicit VSL present in our data is not comparable to other studies and we have not 
computed any VSL in this paper. For all these reasons, one potential criticism to this 
paper is that the risk reduction we have studied is different from other studies, since it 
deals with higher risk reductions and they refer to a private good, while the senior 
discount is usually relevant in policies related to public goods that deal with smaller risk 
reductions. While all this can be true, it is also true that the fact that we used a health 
problem that is fairly well known by member of the general population, and the fact that 
we have used higher risks reductions may have contributed to collect data that are 
highly consistent. In that respect, the estimations of the senior discount may have been 
less affected by problems in dealing with unfamiliar goods and very small probabilities, 
as it happens in other studies. A second limitation is that, in order to achieve a large 
number of observations in a face-to-face survey, we needed to insert our study in a 
survey where people were asked about other issues. We accept that this is not the ideal 
way of conducted a Willingness to Pay study. However, we have tried to reduce the 
limitations of this methods is several ways. We had previous experience in the issue of 
risk reduction for AMI using in-depth face-to-face interviews. The visual aid and the 
framing of the questions were then fully piloted. We knew that most subjects did not 
need too much time to understand the main concept, namely, that after an AMI your risk 
of death increases and medicines can reduce this risk. In summary, in the trade-off 
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between providing in-depth information and having a large sample size we clearly chose 
sample size and we try to compensate for that presenting a case study that subjects 
could grasp more or less easily and presenting risks reductions of a size that subjects 
can understand easily. A third limitation is that we used several framings so not all 
subjects were asked exactly the same type of questions. However, we observed similar 
results (not shown) when only the data from EP1 were used. Given the results of these 
checks, it does not seem that our results suggest a lack of understanding of the good 
being valued. There is nothing in the data to suggest this is the case. 
 
The results show a remarkable consistency between methods. The problems that 
Alberini [1] observed in other databases are not present here. In our case, simple 
methods (e.g., a quadratic utility function) do not seem to be very different from the 
more sophisticated and flexible semi non-parametric approach. Also, the results of the 
non-parametric approach are in line with the rest of results, so they can hardly be 
attributed to statistical assumptions of the model. In addition to that, this is one of the 
few papers that has used the marginal and the total approach and the fact that both 
approaches produce similar results is another indication of a very stable pattern. 
Krupnick [14], talking about the senior discount, points out that “if an effect (or its 
absence) is not robust, then one can probably manipulate the data to find any desired 
outcome. Alberini’s [1] manipulation of data from several of the studies suggests that 
these effects can come and go depending on unrelated or incidental analytical choices”. 
This is not our case. 
 
The pattern observed confirms the presence of the senior discount but our results also 
confirms that the size of this effect is limited. Krupnick [14] suggests that a discount of 
25% may not be very relevant in order to use different VSL for seniors. In our case, the 
results are in this range. Also, the fact that this discount is mainly concentrated on low-
income subjects raises obvious ethical issues that make the application of this discount 
doubtful. However, this is not for us to say. It is true that the non-parametric results 
suggest a much larger discount for the oldest seniors (80 years and more). We have to 
be cautious about this result, since this is the group with lower number of observations. 





Finally, our results raise important issues in those areas that base their policies on the 
concept of Value of a Life Year or Quality-Adjusted Life Years (QALYs), for example, 
regulation of medicines. Those policies usually assume that the monetary value of a 
year of life or of a QALY is independent of age. Our results suggest that VSLY is not 
constant over the life cycle and that the monetary value of life years (or QALYs) 
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Table I. Options compared with status quo in the different elicitation procedures 
 
Group 









1 3% 30 3%    6 / 60     
2 3% 60 3%  30 / 90     
3 3% 90 3%    60 / 120     
4 3% 120 3%     90 / 240     
5 3% 240 3%  120 / 300     
6b 3% 90 3%    60 / 120     
7 3% 240 3% 120 / 360     
8 3% 480 3% 360 / 720     
9 3% 720 3%  480 / 1080     
10 3% 1080 3%   720 / 1500     
11 3% 1500 3% 1080 / 2100     
12b 3% 720 3%  480 / 1080     
EP2 
13 7% 90 7% 240 3% 90 3% 240 
14 3% 90 3% 240 1% 90 1% 240 
15 7% 240 7% 720 3% 240 3% 720 
16 3% 240 3% 720 1% 240 1% 720 
17 7% 720 7% 1500 3% 720 3% 1500 
18 3% 720 3% 1500 1% 720 1% 1500 
19 3% 720 7% 720 3% 240 7% 240 
20 1% 720 3% 720 1% 240 3% 240 
EP3 
21 1‰ 240 5‰ 240 1% 240 3% 240 
22 3% 240 1% 240 5‰ 240 1‰ 240 






















24 7% 720 5% 720 3% 720 1% 720 
25 1‰ 30 5‰ 30 1% 30 3% 30 
26 1‰ 90 5‰ 90 1% 90 3% 90 
27 1‰ 720 5‰ 720 1% 720 3% 720 
28 1‰ 1500 5‰ 1500 1% 1500 3% 1500 
29 1‰ 2400 5‰ 2400 1% 2400 3% 2400 
30 1% 240 3% 240 5% 240 7% 240 
a For EP1, the step-down and step-up bids in the follow-up question are showed. 
b In groups 6 and 12 the change in risk was presented as a percentage (e.g. change in risk from 17% to 





















Table II. Turnbull estimates a,b,c 
Age  Education=0 Education=1  Income=0  Income=1  
18-39 
SS 831 1553 1024 1360 
WTP 767.2231 917.9937 830.2644 921.7996 
95% CI (619.7665,      889.9941) 
 (789.9550,     
1048.6294 ) 
(690.2903      
944.2519) 
(764.3822,     
1048.4235) 
40-59 
SS 1019 597 619 997 
WTP 761.8386 1043.2761 811.5742 911.2045 
95% CI (612.8578,      884.1717) 
(865.9058,     
1200.9756) 
(632.7880,      
956.9751) 
(766.4754,     
1047.6154) 
60-98 
SS 1355 181 1328 208 
WTP 585.4736 785.0506 578.7579 836.2207 
95% CI (480.3164,      684.7205) 
(489.1202,     
1021.9548) 
 (472.2253,      
671.9622) 
(508.5941,     
1085.4380) 








SS 518 313 506 1047 
WTP 750.0278 801.1474 900.7027 932.8729 
95% CI (567.5439,      893.8982) 
(527.0013,      
989.3712) 
(695.6161,     
1081.9317) 
(753.0156,     
1090.9497) 
40-59 SS 544 475 75 522 
26 
 
WTP 775.0675 720.5447 967.8095 1030.8295 
95% CI (584.3483,      921.1827) 
(502.5155,      
918.0465) 
(496.5085,     
1282.2488) 
(844.9832,     
1215.7132) 
60-98 
SS 1247 108 81 100 
WTP 567.6460 809.8620 608.1026 800.3259 
95% CI (461.5693,      662.6024) 
(412.9454,     
1092.7710) 
(435.4001,      
751.8908) 
(409.6608,     
1193.8462) 
a Confidence interval estimated using non-parametric bootstrapping and 10,000 replicates. 
b Income=1 is the high income group. See main text for a more detailed definition. 





















Table III. Hypothesis tests for differences betweeen WTP estimates for different profiles 
and age intervals a,b 
(H0:WTPage_interval i=WTPage interval j; H1:WTPage interval i>WTPage interval j) 
 Education=0 Education=1 Income =0 Income=1 
18-39 vs 
 40-59 0.4705 0.1411 0.4211 0.4880 
18-39 vs  
60-98 0.0205 0.1119 0.0009 0.2565 
40-59 vs  










 40-59 0.4163 0.3682 0.4854 0.2039 
18-39 vs  
60-98 0.0417 0.4289 0.0099 0.2297 
40-59 vs  
60-98 0.0269 0.4837 0.0872 0.1255 
a Age interval i is the interval with the higher WTP mean. 
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b One-sided approximate significance level obtained following Poe et al. [25] with non-parametric 



























APPENDIX 1: ANCILLARY ANALYSIS WITH THE RESPONSES TO DOUBLE-
BOUND DICHOTOMOUS CHOICES 
As mentioned in the paper (footnote 1 and conclusions), similar conclusions were drawn 
when using only the response to the first bid in EP1, that is, for the Single-Bound 
Dichotomous questions. This appendix shows these results.  
 
These WTP estimates are lower than those reported in the paper because the highest bid 
in the double-bounded exercise (EP1) is 1500€, while in the total sample 
(EP1+EP2+EP3) is 2400€. As a consequence of that, the non-parametric estimate of the 
WTP is lower because the response probability model is truncated at a lower bid. In 
order to make comparisons between the parametric and non-parametric estimates, we 
have also truncated the parametric and semi-nonparametric estimates at 1500€. 
Anyway, we have also checked that using parametric models but truncating at 2400€ 








 Table IIbis. Turnbull estimates a 
  Education=0 Education=1 Income=0 Income=1 
18-39 
SS 351 646 409 588 
WTP 643.9791 678.8960 614.9171 719.8401 
95% CI (531.1475,      752.3979 ) 
(603.7921,      
756.7105 ) 
(514.4614,      
704.6930 ) 
(631.2388,      
795.8216 ) 
40-59 
SS 409 234 243 400 
WTP 573.4963 722.6643 517.6212 678.6169 
95% CI  (475.5795,      672.8780 ) 
(574.0551,      
847.0524 ) 
(413.2745,      
630.0686 ) 
(575.4004,      
784.1323 ) 
60-98 
SS 565 74 553 86 
WTP 482.2650 630.6367 490.8533 562.5758 
95% CI (405.5720,      558.5574 ) 
 (429.5581,      
802.9437 ) 
(410.3216,      
567.9629 ) 
(371.1039,      
732.3772 ) 




Table IIIbis. Hypothesis tests for differences betweeen WTP estimates for different 
profiles and age intervals a,b 
(H0:WTPage_interval i=WTPage interval j; H1:WTPage interval i>WTPage interval j) 
 Education=0 Education=1 Income =0 Income =1 
18-39 vs 






















Parametric (dummies, set 1)




18-39 vs  
60-98 0.0090 0.2505 0.0275 0.0558 
40-59 vs  
60-98 0.0712 0.1936 0.3398 0.1146 
a Age interval i is the interval with the higher WTP mean. 
b One-sided approximate significance level obtained following Poe et al. [25] with non-parametric 





All these estimates were obtained taking the highest bid in EP1 as the highest bid (that 
is, 1500€). This way the parametric, semi-nonparametric and non-parametric estimates 
are comparable. In order to compare the WTP estimates obtained from the EP1 with 
those obtained from the total sample (EP1+EP2+EP3), we re-estimate the WTP 
obtained from the EP1 with the linear specification for the variable age and we take as 
the highest bid for the truncation the highest bid in the total sample (that is, 2400€). The 






















































APPENDIX 2: EXAMPLES OF SURVEY QUESTIONS 
 
ELICITATION PROCEDURE 1 
We are going to talk now about medicines for a major problem like Acute Myocardial 
Infarction. 
 
The acute myocardial infarction is a heart problem that usually occurs because fat builds 
up in the arteries that carry blood to the heart and they become clogged. Since there is 
not enough blood going to the heart, it does not receive enough oxygen and that part of 
the heart does not get the oxygen dies and the heart may stop working. 
 
Occasionally, acute myocardial infarction results in immediate death. In other cases, the 
person survives but in the most severe cases, the heart and is permanently damaged. 
Because of this, these people have to take medicines after the infarction. Let us say they 
have to take medicine X. Despite taking medicine X, 170 out of 1000 people who have 
suffered a severe infarction and who have not died immediately will die the first year 
after having the infarction. After the first year, very few die from heart problems related 




Suppose you just had a severe infarction and you have to take medicine X for one year. 
With such medication your risk of death the first year after infarction is 170 out of 1000. 
 
[INTERVIEWER SHOW VISUAL AID 1] 
 
Suppose now that a new drug (say medicine A) is discovered for patients who had an 
infarction. Studies have shown that, if taken over a year after infarction, it reduces 
mortality from 170 to 140 per thousand. That is, 30 fewer people will die out of 1000 if 
the 1000 take drug A instead of X. 
 
[INTERVIEWER SHOW VISUAL AID 2] 
 
The new medicine A does not add any new side effect to the usual treatment with 
medicine X.  
 
Assume that medicine X does not generate any extra cost to your monthly expenditures. 
Taking medicine X does not generate additional expenditures. However, if you decide 
to take medicine A, your monthly expenditures will increase in 30€ for one year, that 
you will not be able to spend in other things.  
 
In summary, you have two options: 
• Take medicine X that does not increase your monthly expenditures and 
assume a risk of 170 in 1000.  
• Take medicine A that will reduce your risk but that will cost you some 
money. 
 
[INTERVIEWER SHOW CARD 1] 
 






a. I would not take the medicine à  go to question 2 





Assume that the cost of the medicine is smaller, instead of 30€ per month, you would 
have to pay 6€ per month for 1 year. Would you pay 6€ per month for medicine A? 
 
QUESTION 3 
Assume that the cost of the medicine is higher, instead of 30€ per month, you would 
have to pay 60€ per month for 1 year. Would you pay 60€ per month for medicine A? 
ELICITATION PROCEDURE 2 
 
We are going to talk now about medicines for a major problem like Acute Myocardial 
Infarction. 
 
The acute myocardial infarction is a heart problem that usually occurs because fat builds 
up in the arteries that carry blood to the heart and they become clogged. Since there is 
not enough blood going to the heart, it does not receive enough oxygen and that part of 
the heart does not get the oxygen dies and the heart may stop working. 
 
Occasionally, acute myocardial infarction results in immediate death. In other cases, the 
person survives but in the most severe cases, the heart and is permanently damaged. 
Because of this, these people have to take medicines after the infarction. Let us say they 
have to take medicine X. Despite taking medicine X, 170 out of 1000 people who have 
I would not take medicine A, I would go for  X, 
so: 
 
• I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
• No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
 
• I would accept a risk of death for the first year of 
140 out of 1000, that is, 30 less out of 1000. 
 
 
• My monthly expenses in medicines would 
increase in 30€. 
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suffered a severe infarction and who have not died immediately will die the first year 
after having the infarction. After the first year, very few die from heart problems related 
to the Infarction. 
 
Suppose you just had a severe infarction and you have to take medicine X for one year. 
With such medication your risk of death the first year after infarction is 170 out of 1000. 
[INTERVIEWER SHOW VISUAL AID 1] 
 
Suppose now that a new drug (say medicine A) is discovered for patients who had an 
infarction. Studies have shown that, if taken over a year after infarction, it reduces 
mortality but it does not have the same effect in all patients.  
 
• In one group (group 1) medicine A reduce mortality from 170 to 140 per 
thousand. That is, 30 fewer people will die out of 1000 if the 1000 take drug 
A instead of X. [INTERVIEWER SHOW VISUAL AID 2] 
• In one group (group 2) medicine A reduce mortality from 170 to 100 per 
thousand. That is, 70 fewer people will die out of 1000 if the 1000 take drug 
A instead of X. [INTERVIEWER SHOW VISUAL AID 3] 
 
There is a medical test that can tell you if you belong to group 1 or 2.  
 
The new medicine A does not add any new side effect to the usual treatment with 
medicine X. 
 
Assume that medicine X does not generate any extra cost to your monthly expenditures. 
Taking medicine X does not generate additional expenditures. However, if you decide 
to take medicine A, your monthly expenditures will increase. Since the drug is very 
new, we do not know the price exactly. All we know is that will generate extra costs to 
you in medicines that will move between a minimum of 90€ per month for one year and 
a maximum of 240€ per year.  
 
In summary, you have two options: 
• Take medicine X that does not increase your monthly expenditures and 
you accept a risk of death of 170 in 1000.  
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• Take medicine A that will reduce your risk but that will cost you some 
money. 
 
Before deciding if it is better option 1 or 2 you have to think that there are, at least, four 
potential situations: 
 
1. The medical test tells you that you belong to group 2. Medicine A will reduce 
your risk from 170 to 100 in 1000. The cost for you is 90€ per month. 
2. The medical test tells you that you belong to group 2. Medicine A will reduce 
your risk from 170 to 100 in 1000. The cost for you is 240€ per month. 
3. The medical test tells you that you belong to group 1. Medicine A will reduce 
your risk from 170 to 140 in 1000. The cost for you is 90€ per month. 
4. The medical test tells you that you belong to group 1. Medicine A will reduce 
your risk from 170 to 140 in 1000. The cost for you is 240€ per month.. 
 
We are going to ask you if you think you would choose medicine A or X in each case. 
[INTERVIEWER: THE SUBJECT HAS TO RESPOND TO NEXT QUESTIONS 
WITH THE NEXT SHEET IN FRONT OF HIM/HER. THE SUBJECT MUST HAVE 
THE FOUR CASES IN FRONT OF HIM/HER EVENTHOUGH RESPONDS TO 
EACH QUESTION INDIVIDUALLY] 
[INTERVIEWER: THE SUBJECT HAS TO BE ABLE TO SEE VISUAL AID 2 AND 
3 WHILE RESPONDING TO NEXT QUESTIONS]  
 
Case 1. The medical test tells you that you belong to group 2. Medicine A will reduce 
your risk from 170 to 100 in 1000. The cost for you is 90€ per month. 
I would not take medicine A, I would go for  X, so 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
year of 100 out of 1000, that is, 70 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 90€. 
 
Case 2. The medical test tells you that you belong to group 2. Medicine A will reduce 
your risk from 170 to 100 in 1000. The cost for you is 240€ per month. 
I would not take medicine A, I would go for  X so: 
 
§ I would accept a risk of death for the first 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
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year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
year of 100 out of 1000, that is, 70 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 240€. 
 
Case 3. The medical test tells you that you belong to group 1. Medicine A will reduce 
your risk from 170 to 140 in 1000. The cost for you is 90€ per month. 
I would not take medicine A, I would go for  X so: 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
year of 140 out of 1000, that is, 30 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 90€. 
 
Case 4. The medical test tells you that you belong to group 1. Medicine A will reduce 
your risk from 170 to 140 in 1000. The cost for you is 240€ per month. 
I would not take medicine A, I would go for  X so: 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
year of 140 out of 1000, that is, 30 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 240€. 
 
 
ELICITATION PROCEDURE 3 
 
We are going to talk now about medicines for a major problem like Acute Myocardial 
Infarction. 
 
The acute myocardial infarction is a heart problem that usually occurs because fat builds 
up in the arteries that carry blood to the heart and they become clogged. Since there is 
not enough blood going to the heart, it does not receive enough oxygen and that part of 
the heart does not get the oxygen dies and the heart may stop working. 
 
Occasionally, acute myocardial infarction results in immediate death. In other cases, the 
person survives but in the most severe cases, the heart and is permanently damaged. 
Because of this, these people have to take medicines after the infarction. Let us say they 
have to take medicine X. Despite taking medicine X, 170 out of 1000 people who have 
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suffered a severe infarction and who have not died immediately will die the first year 
after having the infarction. After the first year, very few die from heart problems related 
to the Infarction. 
 
Suppose you just had a severe infarction and you have to take medicine X for one year. 
With such medication your risk of death the first year after infarction is 170 out of 1000. 
[INTERVIEWER SHOW VISUAL AID 1] 
 
Suppose now that a new drug (say medicine A) is discovered for patients who had an 
infarction. Studies have shown that, if taken over a year after infarction, it reduces 
mortality but it does not have the same effect in all patients. 
 
• In one group (group 1) medicine A reduce mortality from 170 to 169 per 
thousand. That is, 1 fewer person will die out of 1000 if the 1000 take drug 
A instead of X. [INTERVIEWER SHOW VISUAL AID 2] 
• In one group (group 2) medicine A reduce mortality from 170 to 165 per 
thousand. That is, 5 fewer people will die out of 1000 if the 1000 take drug 
A instead of X. [INTERVIEWER SHOW VISUAL AID 3]  
• In one group (group 3) medicine A reduce mortality from 170 to 160 per 
thousand. That is, 10 fewer person will die out of 1000 if the 1000 take drug 
A instead of X. [INTERVIEWER SHOW VISUAL AID 4] 
• In one group (group 4) medicine A reduce mortality from 170 to 140 per 
thousand. That is, 30 fewer people will die out of 1000 if the 1000 take drug 
A instead of X. [INTERVIEWER SHOW VISUAL AID 5] 
 
There is a medical test that can tell you  the group you belong to.  
 
The new medicine A does not add any new side effect to the usual treatment with 
medicine X. 
 
Assume that medicine X does not generate any extra cost to your monthly expenditures. 
Taking medicine X does not generate additional expenditures. However, if you decide 
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to take medicine A, your monthly expenditures will increase in 30€ for one year, that 
you will not be able to spend in other things.  
 
In summary, you have two options: 
 
• Take medicine X that does not increase your monthly expenditures and 
you accept a risk of death of 170 in 1000.  
• Take medicine A that will reduce your risk but that will cost you some 
money. 
 
Before deciding if it is better option 1 or 2 you have to think that there are, at least, four 
potential situations.: 
1. The medical test tells you that you belong to group 1. Medicine A will reduce 
your risk from 170 to 169 in 1000. The cost for you is 30€ per month. 
2. The medical test tells you that you belong to group 2. Medicine A will reduce 
your risk from 170 to 165 in 1000. The cost for you is 30€ per month. 
3. The medical test tells you that you belong to group 3. Medicine A will reduce 
your risk from 170 to 160 in 1000. The cost for you is 30€ per month. 
4. The medical test tells you that you belong to group 4. Medicine A will reduce 
your risk from 170 to 140 in 1000. The cost for you is 30€ per month.. 
 
We are going to ask you if you think you would choose medicine A or X in each case. 
 
[INTERVIEWER: THE SUBJECT HAS TO RESPOND TO NEXT QUESTIONS 
WITH THE NEXT SHET IN FRONT OF HIM/HER. THE SUBJECT MUST HAVE 
THE FOUR CASES IN FRONT OF HIM/HER EVENTHOUGH RESPONDS TO 
EACH QUESTION] 
[INTERVIEWER: THE SUBJECT HAS TO BE ABLE TO SEE VISUAL AID 1 
WHILE RESPONDING TO NEXT QUESTIONS] 
Case 1. The medical test tells you that you belong to group 1. Medicine A will reduce 
your risk from 170 to 169 in 1000. The cost for you is 30€ per month. 
I would not take medicine A, I would go for  X, so 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 





§ No extra costs on medicines. 
 
§ My monthly expenses in medicines would 
increase in 30€. 
 
Case 2. The medical test tells you that you belong to group 2. Medicine A will reduce 
your risk from 170 to 165 in 1000. The cost for you is 30€ per month. 
I would not take medicine A, I would go for  X so: 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
year of 165 out of 1000, that is, 5 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 30€. 
 
Case 3. The medical test tells you that you belong to group 3. Medicine A will reduce 
your risk from 170 to 160 in 1000. The cost for you is 30€ per month. 
I would not take medicine A, I would go for  X so: 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
year of 160 out of 1000, that is, 10 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 30€. 
 
Case 4. The medical test tells you that you belong to group 4. Medicine A will reduce 
your risk from 170 to 140 in 1000. The cost for you is 30€ per month. 
I would not take medicine A, I would go for  X so: 
 
§ I would accept a risk of death for the first 
year of 170 out of 1000. 
 
 
§ No extra costs on medicines. 
Yes, I would take medicine A, so: 
 
§ I would accept a risk of death for the first 
year of 140 out of 1000, that is, 30 less out of 
1000. 
 
§ My monthly expenses in medicines would 
increase in 30€. 
 
